Relationship between serum LXA4 and Gal-3 levels and disease progression in patients with allergic rhinitis
TANG Xiaoxu1, SUN Baochun2, LI Jiali3, LIU Qingpeng1
1. Otolaryngology Department of Jingnan Medical District, PLA General Hospital, Beijing, 100858, China; 2. Otolaryngology Head and Neck Surgery Department of the Fourth Medical Center of PLA General Hospital, Beijing, 100142, China; 3. The 46th Resignation and Rehabilitation Center in Haidianof of Beijing, Garrison Command Military, Beijing 100036, China
Abstract：Objective To investigate the relationship between serum levels of lipoxin A4 (LXA4) and galactin-3 (Gal-3) and disease progression in patients with allergic rhinitis (AR). Methods A total of 113 AR patients admitted to the outpatient department of Jingnan Medical District of PLA General Hospital from July 2022 to October 2023 were included as AR group, and were divided into mild group (48 cases) and moderate and severe group (65 cases) according to the grading standard of the World Health Organization. Meanwhile,110 healthy volunteers were selected as control group. Serum levels of LXA4 and Gal-3 were measured by enzyme-linked immunosorbent kit. General data of AR patients was collected. The correlation analysis between variables was conducted using Spearman correlation test. Receiver operating characteristic (ROC) curve was applied to evaluate the ability of serum LXA4 and Gal-3 levels to distinguish different severity of AR. Logistic regression was used to analyze the influencing factors of AR disease severity. Results Compared with the control group, serum levels of LXA4 and Gal-3 in AR group obviously increased (P<0.05). VAS, TNSS scores, serum LXA4 and Gal-3 levels in the moderate and severe group were obviously higher than those in mild group (P<0.05). Spearman correlation analysis showed that serum levels of LXA4 and Gal-3 were positively correlated with VAS and TNSS scores in AR patients (P<0.05). The AUC of serum LXA4, Gal-3, and their combination in the diagnosis of moderate and severe AR were 0.829, 0.812, and 0.912, respectively, which were obviously higher than that of single detection (Z combination-LXA4=3.076, Z combination-Gal-3=2.940, P<0.05). Serum LXA4 and Gal-3 levels were independent risk factors for the occurrence of moderate and severe AR (P<0.05). Conclusions The levels of serum LXA4 and Gal-3 are elevated in AR patients and are closely related to disease progression.
唐晓旭, 孙宝春, 李佳丽, 刘庆鹏. 过敏性鼻炎患者血清LXA4、Gal-3水平与病情进展的关系[J]. 武警医学, 2024, 35(6): 480-483.
TANG Xiaoxu, SUN Baochun, LI Jiali, LIU Qingpeng. Relationship between serum LXA4 and Gal-3 levels and disease progression in patients with allergic rhinitis. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 480-483.
Siddiqui Z A, Walker A, Pirwani M M, et al. Allergic rhinitis: diagnosis and management[J]. Br J Hosp Med (Lond), 2022, 83(2):1-9.
[2]
Sheha D, El-Korashi L, AbdAllah A M, et al. Lipid profile and IL-17A in allergic rhinitis: correlation with disease severity and quality of life[J]. J Asthma Allergy, 2021, 14:109-117.
[3]
Awan N U, Sohail S K, Naumeri F, et al. Association of serum vitamin D and immunoglobulin E levels with severity of allergic rhinitis[J]. Cureus, 2021, 13(1):e12911.
[4]
Peng X, Zhu X, Luan J, et al. Lipoxin A4 alleviates inflammation in Aspergillus fumigatus-stimulated human corneal epithelial cells by Nrf2/HO-1 signaling pathway[J]. Mol Vis, 2022, 28:441-450.
Soares L C, Al-Dalahmah O, Hillis J, et al. Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases[J]. Cells, 2021, 10(11):3047.
Dykewicz M S, Wallace D V, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update[J]. Ann Allergy Asthma Immunol, 2017, 119(6):489-511.
Xing X, Wang H. Correlation of serum HMGB1 and HMGB2 levels with clinical symptoms in allergic rhinitis children[J]. Medicine (Baltimore), 2023, 102(37):e34921.
[11]
Wang R, Xue S, Liu Y, et al. The correlation of long non-coding RNA NEAT1 and its targets microRNA (miR)-21, miR-124, and miR-125a with disease risk, severity, and inflammation of allergic rhinitis[J]. Medicine (Baltimore), 2021, 100(4):e22946.
[12]
Zhao J, Geng W, Wan K, et al. Lipoxin A4 promotes autophagy and inhibits overactivation of macrophage inflammasome activity induced by Pg LPS[J]. J Int Med Res, 2021, 49(2):300060520981259.
[13]
Zhang L, Tai Q, Xu G, et al. Lipoxin A4 attenuates the lung ischaemia reperfusion injury in rats after lung transplantation[J]. Ann Med, 2021, 53(1):1142-1151.
[14]
Li Q Q, Ding D H, Wang X Y, et al. Lipoxin A4 regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the Notch signaling pathway[J]. Exp Neurol, 2021, 339:113645.
[15]
Hu F, Qu Z, Chen K, et al. Lipoxin A4 ameliorates imiquimod-induced psoriasis-like dermatitis via promoting the regression of inflammation[J]. Clin Cosmet Investig Dermatol, 2023, 16:2103-2111.
[16]
Ramar M, Yano N, Fedulov A V. Intra-airway treatment with synthetic lipoxin A4 and resolvin E2 mitigates neonatal asthma triggered by maternal exposure to environmental particles[J]. Int J Mol Sci, 2023, 24(7):6145.
[17]
Lo T H, Chen H L, Yao C I, et al. Galectin-3 promotes noncanonical inflammasome activation through intracellular binding to lipopolysaccharide glycans[J]. Proc Natl Acad Sci U S A, 2021, 118(30):e2026246118.
[18]
Li H, Xiao L, He H, et al. Quercetin attenuates atherosclerotic inflammation by inhibiting galectin-3-NLRP3 signaling pathway[J]. Mol Nutr Food Res, 2021, 65(15):e2000746.
[19]
Karabacak P. Serum galectin-3 levels predict poor prognosis in sepsis and septic shock patients[J]. Rev Assoc Med Bras (1992), 2023, 69(8):e20220940.
[20]
Mammen M J, Ali J, Aurora A, et al. IL-17 is a key regulator of mucin-galectin-3 interactions in asthma[J]. Int J Cell Biol, 2021, 2021:9997625.
2024, Vol. 35 
